References

Unresolved reference

External reference

Unresolved reference

External reference

Antiretroviral drugs for treatment and pre vention of HIV infection in adults: 2022 recommendations of the International Antiviral Society—USA panel

10.1001/jama.2022.22246 · 2023 · External reference

Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide—based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study

10.1093/cid/ciz1243 · 2020 · External reference

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

10.1016/s0140-6736(18)32462-0 · 2019 · External reference

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

10.1093/cid/ciac130 · 2023 · External reference

Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment

10.1097/qai.0000000000001678 · 2018 · External reference

Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure

10.1093/cid/ciz129 · 2019 · External reference

Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort

10.1186/s12879-020-4837-y · 2020 · External reference

Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis

10.1186/s12981-021-00336-0 · 2021 · External reference

2019 update of the drug resistance mutations in HIV-1

2019 · External reference

Unresolved reference

External reference

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

10.1016/s0140-6736(17)32299-7 · 2017 · External reference

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

10.1016/s0140-6736(17)32340-1 · 2017 · External reference

GS-US-380–4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

10.1093/cid/ciaa988 · 2021 · External reference

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

10.1093/jac/dkz347 · 2019 · External reference

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

10.1016/s2352-3018(18)30091-2 · 2018 · External reference

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

10.1016/s2352-3018(18)30092-4 · 2018 · External reference

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults

10.1371/journal.pone.0291480 · 2023 · External reference

Striving for diversity in research studies

10.1056/nejme2114651 · 2021 · External reference

Impact of low-level viraemia on virological failure in HIV-1- infected patients with stable antiretroviral treatment

10.3851/imp3023 · 2016 · External reference

Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study

10.1016/s1473-3099(17)30681-3 · 2018 · External reference

Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens

10.1016/j.ijantimicag.2022.106631 · 2022 · External reference

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

10.1016/j.ijid.2021.02.045 · 2021 · External reference

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study

10.1016/j.jgar.2022.07.022 · 2022 · External reference

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials

10.1093/cid/ciz999 · 2020 · External reference

Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV

10.1097/qai.0000000000002650 · 2021 · External reference